The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms

Mads Emil Bjørn, Hans Carl Hasselbalch
  • Clinical Case Reports, May 2015, Wiley
  • DOI: 10.1002/ccr3.281

Ruxolitinib and autoimmune diseases

What is it about?

Highlighting the intimate relationship between auto-inflammatory diseases and myeloproliferative neoplasia and demonstrating the dual-acting properties of JAK-inhibition: Myelosuppression and anti-inflammation.

Why is it important?

The potent anti-inflammatory properties of ruxolitinib make JAK-inhibitors a therapeutic option when treating non-malignant inflammatory diseases. This was most recently demonstrated by the effect on Graft-versus-Host-disease post transplant (both acute and chronic) where ruxolitinib "rescues" a significant proportion of corticosteroid-resistant cases, but has demonstrated efficacy in psoriasis (in a topical form).

Read Publication

http://dx.doi.org/10.1002/ccr3.281

The following have contributed to this page: Mr Mads E Bjørn